Replies to post #173859 on Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Not being a scientist type I'm not sure how to answer that Scott. We're still more in the evaluation stage I believe. Once we have the data from this trial from the DMC we'll have a lot more answers.

Cohort 1 (n=5) Kevetrin Cycle - Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses); Follow-up for 3 weeks after Kevetrin treatment ends Cohort 2 (n=5) Kevetrin Cycle - Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses); Follow-up for 3 weeks after Kevetrin treatment ends Cohorts 1 and 2 will be conducted in a sequential fashion, with safety data from cohort 1 evaluated by an independent Data Monitoring Committee (DMC). The DMC will make appropriate recommendations based on the available safety data as regards the intent of progressing to the higher dose cohort 2.
https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=2

There is excellent potential as a stand alone and combo therapy because of the way patients tolerate kevetrin thus far though imo. And the action may very well provide full treatment to complete remission. But, like I said, I'm not educated in the field well enough to say. But so far, as much as we know right now, it looks promising.

2016's fact sheet
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583645a7b8a79b68e6731735/1479951784109/CTIX+Corporate+Fact+Sheet+November+2016+Website+Vers+%28Kevetrin%29.pdf

Kevetrin's cancer program
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583ddcc2bebafbc5c12d45b4/1480449222869/Cellceutix_Corporate_Slide+Deck_ONCOLOGY_November+2016+Website+Vers.pdf

In reply to:

Great info. In one of the articles, Dr. Sylvia Holden commented, "As a stand-alone or combination front-line therapy, the magnitude of the potential of Kevetrin™ is simply unparalleled by anything that I have ever seen in the laboratory before.”

I'm thinking "front-line therapy" would mean the first treatment, then followed by chemo/other treatments, which is what K Ph2 is doing. I don't believe we are following the patients throughout their traditional treatments after K treatment though, so we wouldn't know any long-term effects of K, correct?